557 related articles for article (PubMed ID: 24907175)
21. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
[TBL] [Abstract][Full Text] [Related]
22. The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: results from a prospective study.
Bonfanti P; De Socio GV; Ricci E; Antinori A; Martinelli C; Vichi F; Penco G; Madeddu G; Orofino G; Valsecchi L; Rusconi S; Menzaghi B; Pocaterra D; Quirino T
Biomed Pharmacother; 2012 Jul; 66(5):348-53. PubMed ID: 22705335
[TBL] [Abstract][Full Text] [Related]
23. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America.
Alvarez C; Salazar R; Galindez J; Rangel F; Castaãeda ML; Lopardo G; Cuhna CA; Roldan Y; Sussman O; Gutierrez G; Cure-Bolt N; Seas C; Carcamo C; Castrillo M
Braz J Infect Dis; 2010; 14(3):256-63. PubMed ID: 20835509
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural South India.
Kalyanasundaram AP; Jacob SM; Hemalatha R; Sivakumar MR
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):329-34. PubMed ID: 21508297
[TBL] [Abstract][Full Text] [Related]
25. Independent predictors of metabolic syndrome in HIV-infected patients.
Alencastro PR; Fuchs SC; Wolff FH; Ikeda ML; Brandão AB; Barcellos NT
AIDS Patient Care STDS; 2011 Nov; 25(11):627-34. PubMed ID: 21936688
[TBL] [Abstract][Full Text] [Related]
26. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
Wand H; Calmy A; Carey DL; Samaras K; Carr A; Law MG; Cooper DA; Emery S;
AIDS; 2007 Nov; 21(18):2445-53. PubMed ID: 18025881
[TBL] [Abstract][Full Text] [Related]
27. Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso).
Guira O; Tiéno H; Diendéré AE; Sagna Y; Diallo I; Yaméogo B; Zoungrana L; Yaméogo TM; Bognounou R; Drabo JY
J Int Assoc Provid AIDS Care; 2016; 15(2):159-63. PubMed ID: 26307211
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of Metabolic Syndrome in Patients with HIV in the Era of Highly Active Antiretroviral Therapy.
Lombo B; Alkhalil I; Golden MP; Fotjadhi I; Ravi S; Virata M; Lievano M; Diez J; Ghantous A; Donohue T
Conn Med; 2015 May; 79(5):277-81. PubMed ID: 26245015
[TBL] [Abstract][Full Text] [Related]
29. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy.
Estrada V; Martínez-Larrad MT; González-Sánchez JL; de Villar NG; Zabena C; Fernández C; Serrano-Ríos M
Metabolism; 2006 Jul; 55(7):940-5. PubMed ID: 16784968
[TBL] [Abstract][Full Text] [Related]
30. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study.
Hildrum B; Mykletun A; Hole T; Midthjell K; Dahl AA
BMC Public Health; 2007 Aug; 7():220. PubMed ID: 17727697
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatment.
Calza L; Colangeli V; Magistrelli E; Rossi N; Rosselli Del Turco E; Bussini L; Borderi M; Viale P
HIV Clin Trials; 2017 May; 18(3):110-117. PubMed ID: 28420298
[TBL] [Abstract][Full Text] [Related]
32. Lack of association between dyslipidemia and insulin resistance in HIV-infected persons treated with highly active antiretroviral therapy.
Swanson B; Keithley JK; Zeller JM; Sha BE
Nutrition; 2004; 20(11-12):1022-5. PubMed ID: 15561494
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of metabolic syndrome according to Adult Treatment Panel III and International Diabetes Federation criteria: a population-based study.
Bener A; Zirie M; Musallam M; Khader YS; Al-Hamaq AO
Metab Syndr Relat Disord; 2009 Jun; 7(3):221-9. PubMed ID: 19320557
[TBL] [Abstract][Full Text] [Related]
34. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
[TBL] [Abstract][Full Text] [Related]
35. Metabolic syndrome in dyslipidemia consultations.
Monteiro S; Dias P; Madeira S; de Moura P; Silva JM; Providência LA; Alves de Moura JJ
Rev Port Cardiol; 2006 Sep; 25(9):821-31. PubMed ID: 17100172
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia.
Gündogan K; Bayram F; Capak M; Tanriverdi F; Karaman A; Ozturk A; Altunbas H; Gökce C; Kalkan A; Yazici C
Metab Syndr Relat Disord; 2009 Oct; 7(5):427-34. PubMed ID: 19754305
[TBL] [Abstract][Full Text] [Related]
37. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database.
Sicras A; Rejas J; Navarro R; Serrat J; Blanca M
Bipolar Disord; 2008 Jul; 10(5):607-16. PubMed ID: 18657245
[TBL] [Abstract][Full Text] [Related]
38. Metabolic syndrome: prevalence, associated factors, and C-reactive protein: the MADRIC (MADrid RIesgo Cardiovascular) Study.
Martínez MA; Puig JG; Mora M; Aragón R; O'Dogherty P; Antón JL; Sánchez-Villares T; Rubio JM; Rosado J; Torres R; Marcos J; Pallardo LF; Banegas JR;
Metabolism; 2008 Sep; 57(9):1232-40. PubMed ID: 18702949
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients.
Manuthu EM; Joshi MD; Lule GN; Karari E
East Afr Med J; 2008 Jan; 85(1):10-7. PubMed ID: 18543521
[TBL] [Abstract][Full Text] [Related]
40. Dyslipidemia in ART-Naive HIV-Infected Persons in Nigeria--Implications for Care.
Kuti MA; Adesina OA; Awolude OA; Ogunbosi BO; Fayemiwo SA; Akinyemi JO; Adetunji AA; Irabor AE; Odaibo GN; Prosper O; Taiwo BO; Olaleye D; Murphy RL; Kanki P; Adewole IF
J Int Assoc Provid AIDS Care; 2015; 14(4):355-9. PubMed ID: 25331224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
